Can-Fite BioPharma ( (CANF) ) has shared an announcement.
On March 3, 2025, Can-Fite BioPharma Ltd. announced the publication of an article in the European Society of Medicine Journal highlighting the protective effects of Namodenoson in liver cancer treatment. The study, a collaboration with Soroka University Medical Center, demonstrates Namodenoson’s anti-ischemic, anti-inflammatory, and anti-toxicity benefits, distinguishing it from traditional chemotherapy. Namodenoson is currently in a pivotal Phase III study for advanced liver cancer, with Orphan Drug and Fast Track status from the FDA and EMA, positioning it as a potential breakthrough therapy.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs targeting oncological and inflammatory diseases. The company is engaged in advanced clinical-stage drug development, addressing multi-billion-dollar markets in cancer, liver, and inflammatory disease treatments. Its lead drug candidates include Piclidenoson for psoriasis and Namodenoson for hepatocellular carcinoma, MASH, and pancreatic cancer, with Namodenoson holding Orphan Drug and Fast Track designations.
YTD Price Performance: -1.68%
Average Trading Volume: 487,558
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $16.95M
For detailed information about CANF stock, go to TipRanks’ Stock Analysis page.